Leelyn Smith’s Nurix Therapeutics NRIX Stock Holding History

Leelyn Smith’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-200	Closed	-$2.2K	–	311
2022 Q4	$2.2K	Buy	+200	New	+$2.41K	﹤0.01%	406

Other funds holding NRIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Leelyn Smith's NRIX Position: Q1 2023 in Review

Leelyn Smith sold out of Nurix Therapeutics (NRIX) in Q1 2023, closing a stake of 200 shares — an estimated $2.2K sold.

Leelyn Smith first reported a position in NRIX in Q4 2022 and held it in 1 quarter. The position peaked at $2.2K in Q4 2022. 123 funds tracked by Wall St. Rank hold NRIX as of Q1 2023.

Leelyn Smith reported no remaining Nurix Therapeutics position as of Q1 2023 after selling out during the quarter.
Leelyn Smith sold 200 Nurix Therapeutics shares in Q1 2023, an estimated $2.2K.
Leelyn Smith first reported a position in Nurix Therapeutics in Q4 2022 and held it in 1 quarter.
Leelyn Smith's Nurix Therapeutics position peaked at $2.2K in Q4 2022.
123 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2023.

Based on Leelyn Smith's 13F filing for Q1 2023, filed 12 May 2023.